Michael J. Birrer

103.5k total citations · 10 hit papers
434 papers, 25.4k citations indexed

About

Michael J. Birrer is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Michael J. Birrer has authored 434 papers receiving a total of 25.4k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Molecular Biology, 190 papers in Reproductive Medicine and 164 papers in Oncology. Recurrent topics in Michael J. Birrer's work include Ovarian cancer diagnosis and treatment (186 papers), Endometrial and Cervical Cancer Treatments (41 papers) and PARP inhibition in cancer therapy (40 papers). Michael J. Birrer is often cited by papers focused on Ovarian cancer diagnosis and treatment (186 papers), Endometrial and Cervical Cancer Treatments (41 papers) and PARP inhibition in cancer therapy (40 papers). Michael J. Birrer collaborates with scholars based in United States, Canada and United Kingdom. Michael J. Birrer's co-authors include Samuel C. Mok, Kathleen N. Moore, Gini F. Fleming, Bradley J. Monk, John D. Minna, Robert S. Mannel, Mark F. Brady, Anil K. Sood, Éva Szabó and Robert A. Burger and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Michael J. Birrer

419 papers receiving 25.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

2011 1.6k citations Michael J. Birrer et al. profile →
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis

1996 1.6k citations Michael J. Birrer et al. profile →
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer

1989 1.1k citations Michael J. Birrer et al. profile →
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

2012 853 citations Sián Fereday, Anna DeFazio et al. profile →
Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73

1991 716 citations Michael J. Birrer et al. profile →
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

2014 446 citations Michael J. Birrer, Elise C. Kohn et al. profile →
Antibody-Drug Conjugate-Based Therapeutics: State of the Science

2019 323 citations Michael J. Birrer, Kathleen N. Moore et al. profile →
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

2016 250 citations Richard T. Penson, Michael J. Birrer et al. profile →
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

2021 186 citations Kathleen N. Moore, Michael J. Birrer et al. profile →
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

2021 160 citations Michael J. Birrer et al. profile →

Peers

Countries citing papers authored by Michael J. Birrer

Since Specialization

Citations

This map shows the geographic impact of Michael J. Birrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Birrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Birrer more than expected).

Fields of papers citing papers by Michael J. Birrer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Birrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Birrer. The network helps show where Michael J. Birrer may publish in the future.

Co-authorship network of co-authors of Michael J. Birrer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Birrer. A scholar is included among the top collaborators of Michael J. Birrer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Birrer. Michael J. Birrer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2022-RA-1519-ESGO Biomarker testing and first line maintenance treatment patterns in a real-world US cohort of patients with advanced ovarian cancer 2022 ·International Journal of Gynecological Cancer ·Dan S. Veljovich, Richard T. Penson, Michael J. Birrer, Gráinne H. Long, G. Barrie Wetherill, (unknown)	1
2	Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer 2019 ·Clinical Cancer Research ·Tsz-Lun Yeung, Cecilia S. Leung, Kay‐Pong Yip, Jianting Sheng, Long Vien, Laura Bover, Michael J. Birrer, Stephen T.C. Wong, Samuel C. Mok	48
3	Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations 2018 ·The Oncologist ·Kathleen N. Moore, Michael J. Birrer	14
4	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors 2018 ·Clinical Cancer Research ·David M. Hyman, Naiyer A. Rizvi, Ronald B. Natale, Deborah K. Armstrong, Michael J. Birrer, Lawrence D. Recht, Efrat Dotan, Vicky Makker, Thomas Kaley, (unknown), Matthew Gribbin, Jennifer McDevitt, Dominic W. Lai, Mohammed M. Dar	38
5	Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic 2016 ·Molecular Cancer Therapeutics ·Pauline J. van der Watt, (unknown), (unknown), (unknown), (unknown), Sarah Carden, Liselotte Angus, Kate Hadley, Dirk Lang, Wei Wei, Michael J. Birrer, John O. Trent, Virna D. Leaner	59
6	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array 2015 ·Clinical Cancer Research ·Vinod Vathipadiekal, Victoria Wang, Wei Wei, Levi Waldron, Ronny Drapkin, Michael A. Gillette, Steven J. Skates, Michael J. Birrer	69
7	Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer 2014 ·Clinical Cancer Research ·Elizabeth Pham, Michael J. Birrer, Scott Eliasof, Edward G. Garmey, Douglas Lazarus, Christina R. Lee, Shan Man, Ursula A. Matulonis, Christian Peters, Ping Xu, Carolyn Krasner, Robert S. Kerbel	77
8	TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment 2013 ·Cancer Research ·Tsz-Lun Yeung, Cecilia S. Leung, Kwong‐Kwok Wong, Goli Samimi, Melissa S. Thompson, Jinsong Liu, Tarrik M. Zaid, Sue Ghosh, Michael J. Birrer, Samuel C. Mok	313
9	Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer 2013 ·Clinical Cancer Research ·Tarrik M. Zaid, Tsz-Lun Yeung, Melissa S. Thompson, Cecilia S. Leung, Tom Harding, (unknown), (unknown), Suet‐Ying Kwan, (unknown), Gabriel Lopez‐Berestein, Anil K. Sood, Kwong‐Kwok Wong, Michael J. Birrer, Samuel C. Mok	74
10	Common Variation in Nemo-Like Kinase Is Associated with Risk of Ovarian Cancer 2012 ·Cancer Epidemiology Biomarkers & Prevention ·Kristen N. Stevens, Linda E. Kelemen, Xianshu Wang, Brooke L. Fridley, Robert A. Vierkant, Zachary Fredericksen, Sebastian M. Armasu, Ya-Yu Tsai, Andrew Berchuck, Steven A. Narod, Catherine M. Phelan, Rebecca Sutphen, Michael J. Birrer, Joellen M. Schildkraut, Thomas A. Sellers, Ellen L. Goode, Fergus J. Couch	8
11	SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK 2012 ·Molecular Cancer Research ·Hua Li, Qi Cai, Hong Wu, Vinod Vathipadiekal, Zachary C. Dobbin, (unknown), Hua Xiang, Charles N. Landen, Michael J. Birrer, Margarita Sánchez‐Beato, Rugang Zhang	61
12	Wnt5a Suppresses Epithelial Ovarian Cancer by Promoting Cellular Senescence 2011 ·Cancer Research ·Benjamin G. Bitler, (unknown), Hua Li, Qi Cai, Hong Wu, Hua Xiang, Tianyu Li, Michael J. Birrer, Andrew K. Godwin, Paul Cairns, Rugang Zhang	85
13	ALDH1A1 Is a Novel EZH2 Target Gene in Epithelial Ovarian Cancer Identified by Genome-Wide Approaches 2011 ·Cancer Prevention Research ·Hua Li, Benjamin G. Bitler, Vinod Vathipadiekal, (unknown), Michael Slifker, Caretha L. Creasy, Peter J. Tummino, Paul Cairns, Michael J. Birrer, Rugang Zhang	44
14	Activation of NF-κB Signaling by Inhibitor of NF-κB Kinase β Increases Aggressiveness of Ovarian Cancer 2010 ·Cancer Research ·Lídia Hernandez, Sarah Hsu, Ben Davidson, Michael J. Birrer, Elise C. Kohn, Christina M. Annunziata	102
15	A Key Role for Early Growth Response-1 and Nuclear Factor-κB in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer 2009 ·Molecular Cancer Research ·Bo Wang, Levon M. Khachigian, Luke Esau, Michael J. Birrer, Xiaohang Zhao, M. Iqbal Parker, Denver T. Hendricks	44
16	NORE1A Tumor Suppressor Candidate Modulates p21CIP1 via p53 2009 ·Cancer Research ·Diego F. Calvisi, Howard Donninger, Michele D. Vos, Michael J. Birrer, Laura Gordon, Virna D. Leaner, Geoffrey Clark	50
17	Asparagine synthetase is a predictive biomarker of l -asparaginase activity in ovarian cancer cell lines 2008 ·Molecular Cancer Therapeutics ·Philip L. Lorenzi, (unknown), Michele Gunsior, Laurent Ozbun, William C. Reinhold, Sudhir Varma, (unknown), (unknown), Amy Hutchinson, Elise C. Kohn, Paul K. Goldsmith, Michael J. Birrer, John N. Weinstein	81
18	Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors 2008 ·Molecular Cancer Research ·Michael S. Anglesio, Jeremy M. Arnold, Joshy George, Anna V. Tinker, Richard W. Tothill, Nicola Waddell, Lisa A. Simms, Bianca Locandro, Sián Fereday, Nadia Traficante, Peter Russell, Raghwa Sharma, Michael J. Birrer, (unknown), Anna DeFazio, Georgia Chenevix‐Trench, David D.L. Bowtell	91
19	Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance 2006 ·Clinical Cancer Research ·Fred Wamunyokoli, Tomás Bonome, (unknown), Colleen M. Feltmate, William R. Welch, Mike Radonovich, Cindy A. Pise-Masison, John Brady, Ke Hao, Ross S. Berkowitz, Samuel C. Mok, Michael J. Birrer	50
20	Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer 2005 ·Clinical Cancer Research ·Kristin K. Zorn, Tomás Bonome, Lisa Gangi, Gadisetti V.R. Chandramouli, Christopher S. Awtrey, Ginger J. Gardner, J. Carl Barrett, Jeff Boyd, Michael J. Birrer	282

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact